|
|
DT120 (Lysergide) Safety From Phase 3 Studies in Major Depressive Disorder and Generalized Anxiety Disorder
Paula Jacobsen, PhD: Definium Therapeutics, Inc., New York, NY, USATodd M. Solomon, PhD: Definium Therapeutics, Inc., New York, NY, USAJamileh Jemison, MD: Definium Therapeutics, Inc., New York, NY, USAKaren Jacobs, MSN: Definium Therapeutics, Inc., New York, NY, USASarah M. Karas, PsyD: Definium Therapeutics, Inc., New York, NY, USAJoseph Horrigan, MD: Definium Therapeutics, Inc., Ne...
|
Phase 3 Topline Results of DT120 (Lysergide) in Generalized Anxiety Disorder
Paula L. Jacobsen, PhD: Definium Therapeutics, Inc., New York, NYTodd M. Solomon, PhD: Definium Therapeutics, Inc., New York, NY Jamileh Jemison, MD, MS: Definium Therapeutics, Inc., New York, NY Sarah M. Karas, PsyD: Definium Therapeutics, Inc., New York, NY Mukta Chakraborty, PhD, MS: Definium Therapeutics, Inc., New York, NY Jamie M. Freedman, BS: Definium Therapeutics, Inc., New Y...
|
Lumateperone for the Treatment of Bipolar Mania in Patients With Bipolar I Disorder: Results From a Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial
Roger S. McIntyre, MD, Department of Psychiatry, University of Toronto, Toronto, ON, Canada and Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Willie R. Earley, MD, Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, NJ, USA; Robert Hayes, PhD, Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, NJ, USA; Yifan Mo, P...
|
Efficacy and safety of ML-007C-MA, a novel investigational M1/M4 muscarinic receptor agonist for the treatment of schizophrenia: Results from the Phase 2 ZEPHYR trial
Andrew Czysz, MD, PhD: MapLight Therapeutics, Redwood City, CA; Emily Johnson, MS: MapLight Therapeutics, Redwood City, CA; Yan Li, MS, PhD: MapLight Therapeutics, Redwood City, CA; Joanna Sambor, MS: MapLight Therapeutics, Redwood City, CA; Inez Lam, PhD: MapLight Therapeutics, Redwood City, CA; Kimberly Thompson, PhD: MapLight Therapeutics, Redwood City, CA; Christopher Kroeger, MD,...
|
Sex-related differences in brain structure and circuits: implications for neurobiological models of autism
Dr. Minahil Mujahid MA BM BCh: Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom;Dr Husain Ahmed MBChB PGCert Med Ed AFHE: Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle Upon Tyne, United KingdomDr Isra Mujahid MBBS: North Western Deanery, Manchester, United KingdomAhmed Mujahid
|
Characterization of Adverse Event Timing and Duration With Centanafadine in Children and Adolescents With ADHD: Pooled Results From Two Phase 3 Trials
Craig Chepke, MD: Excel Psychiatric Associates, Huntersville, NC, Atrium Health, Charlotte, NC; Osman Turkoglu, MD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Zhen Zhang, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV; Greg W. Matt...
|
Experiences of Xanomeline and Trospium Chloride Prescribing: A Healthcare Provider Survey and Complementary Claims Analysis
Ilan Melnick, MD: Herbert Wertheim College of Medicine, Florida International University, Miami, FL; Misty A. McGillem, DNP, PMHNP-BC: Bristol Myers Squibb, Princeton, NJ; Leanne Li, MPH, MBA: IQVIA, Durham, NC; Shahrzad Salmasi, PhD: IQVIA, Durham, NC; Rina Yarosh, PhD, MPH: IQVIA, Durham, NC; Jennifer N. Hill, MA: IQVIA, Durham, NC; Martim Almeida, MSc: IQVIA, Porto Salvo, Oeiras; T...
|
Incidence and Dose-Related Patterns of Discontinuation in Adults With Schizophrenia Receiving KarXT Who Had GI Adverse Events: A Post Hoc Safety Analysis of EMERGENT-5
Ilan Melnick, MD: Florida International University, Herbert Wertheim College of Medicine, Miami, FL; Andrew Muzyk, PharmD, MHPE: Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC; Misty McGillem, DNP, PMHNP-BC: Bristol Myers Squibb, Princeton, NJ; James Appio, PharmD: Bristol Myers Squibb, Princeton, NJ; Pierre Nicolas, PhD: Bristol Myers Squibb, Princeton, ...
|
Safety and Efficacy of Xanomeline/Trospium Chloride by Week During Transition From Atypical Antipsychotics: A Post Hoc Analysis of the Open-Label, Randomized SWITCH Study
David Walling, PhD: CenExel, Los Alamitos, CA; Naomi Marbot, MD: Bristol Myers Squibb, Princeton, NJ; Lara Shirikjian, DO: CenExel, Torrance, CA; Edwin Gomez, MD: CenExel, Hollywood, FL; Lauren White, BS: CenExel, Atlanta, GA; Kimball Johnson, MD: CenExel, Decatur, GA; Pierre Nicolas, PhD: Bristol Myers Squibb, Princeton, NJ; Gerard Zitnik, PhD, MBA: Bristol Myers Squibb, Princeton, N...
|
| 1 2 3 4 5 6 7 8 9 10 ... |